Clinical studies now underway in collaboration with Royal Hospital for Women in Sydney

Leading the way in preventing congenital heart disease

Please note at this busy period, the donation form may take a little while to load. You can also choose to donate via Paypal.

Clinical studies are underway, and the first stage in preventing heart defects in babies

Scientists at the Victor Chang Cardiac Research Institute have progressed a world-first breakthrough in congenital heart disease to Stage One clinical studies. It’s an exciting development in the prevention of children being born with heart defects, but funding is urgently needed to progress to the next stage – clinical trials.

What is congenital heart disease?

Congenital heart disease is the term used to describe heart defects that impact the function of the heart, which are present from birth.

Eight babies are born with congenital heart disease every day in Australia. Half will face open-heart surgery before their first birthday; tragically, four lives will be lost every week.

What research is the Institute doing to help prevent congenital heart disease?

Professor Sally Dunwoodie and her team discovered a vital molecule called NAD could cause congenital heart disease.

They also uncovered a potential new treatment - a simple vitamin supplement - vitamin B3.

Since making this incredible breakthrough, the team has worked tirelessly to learn everything they can about NAD and, excitingly, has just started clinical studies.

Clinical studies are a crucial step forward to progressing this discovery into a new treatment that has the potential to help prevent congenital heart disease.

How can you help progress this discovery to clinical trials?

Once clinical studies are complete, the team will need to progress its findings to larger-scale clinical trials to test the treatment of vitamin B3 and its potential to prevent heart disease in babies.

The trials will involve recruiting at least 1,000 women from all over Australia.

But we urgently need to raise at least $800,000 in additional funding to make clinical trials possible.

The sooner we do, the sooner we can help reduce the number of children born with heart disease in Australia.

Will you help by making a kind donation this Christmas?

Acknowledgement of Country

The Victor Chang Cardiac Research Institute acknowledges the traditional custodians of the land, the Gadigal of the Eora nation, on which we meet, work, and discover.
Our Western Australian laboratories pay their respect to the Whadjuk Noongar who remain as the spiritual and cultural custodians of their land.